Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma
The Journal of Clinical Endocrinology & Metabolism · 16.09.2025 · 110 (10) · 2946-2963
DOI: 10.1210/clinem/dgaf259 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 03.05.2025. Verfasst von Hussam Alkaissi und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Adrenal Gland Neoplasms, Paraganglioma, Pheochromocytoma. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural Research Program, NCI.
Abstract (Originalsprache)
Phe ochromocytomas and paragangliomas (PPGLs) are rare neural crest–derived tumors with malignant potential and a highly variable natural history, where some patients achieve a cure through surgical resection, while others experience an aggressive and protracted disease course characterized by recurrence and metastasis. While currently no definitive curative treatment exists for metastatic PPGLs, ongoing trials and advances in biology of the disease present a beacon of hope. We present a case that illustrates a 15-year treatment journey, illustrating the complexity of metastatic PPGL treatment with different modalities, each with distinct efficacy and toxicity profiles. The choice of treatment is often an art, as much as it is based on evidence, as the clinician must balance among several factors, including tumor-related (pace of progression, tumor burden) and patient-related (functional status, symptoms, general health) ones. Through a stepwise approach, this discussion aims to provide insights into the evolving landscape of metastatic PPGL management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- Department of Nuclear Medicine, Aix-Marseille University, La Timone University Hospital, 13005 Marseille, France.
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- Department of Medicine IV, University Hospital, Ludwig-Maximilians-University Munich, 80336 Munich, Germany.
- Department of Endocrinology, Royal North Shore Hospital and Cancer Genetics Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales 2064, Australia.
ORCID-Profile: Hussam Alkaissi, David Taieb, Jaydira Del Rivero, Katharina Wang, Roderick Clifton-Bligh, Karel Pacak
Förderung
- NCI NIH HHS
- Intramural Research Program
- NCI
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Intramural NIH HHS
- National Cancer Institute
Zitieren
APA
Alkaissi, H., Taieb, D., Lin, F. I., Del Rivero, J., Wang, K., Clifton-Bligh, R., & Pacak, K. (2025). Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma. The Journal of Clinical Endocrinology & Metabolism, 110(10), 2946-2963. https://doi.org/10.1210/clinem/dgaf259
Vancouver
Alkaissi H, Taieb D, Lin FI, Del Rivero J, Wang K, Clifton-Bligh R, et al. Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma. The Journal of Clinical Endocrinology & Metabolism. 2025;110(10):2946-2963. doi:10.1210/clinem/dgaf259
BibTeX
@article{Alkaissi2025,
author = {Alkaissi, Hussam and Taieb, David and Lin, Frank I and Del Rivero, Jaydira and Wang, Katharina and Clifton-Bligh, Roderick and Pacak, Karel},
title = {Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {10},
pages = {2946--2963},
doi = {10.1210/clinem/dgaf259}
}
EUVIMED